Fin Trust Capital Advisors, LLC Neurocrine Biosciences Inc Transaction History
Fin Trust Capital Advisors, LLC
- $510 Million
- Q1 2024
A detailed history of Fin Trust Capital Advisors, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Fin Trust Capital Advisors, LLC holds 15 shares of NBIX stock, worth $2,062. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15
Previous 15
-0.0%
Holding current value
$2,062
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding NBIX
# of Institutions
628Shares Held
94.4MCall Options Held
505KPut Options Held
343K-
Black Rock Inc. New York, NY13.8MShares$1.89 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.93MShares$1.37 Billion0.03% of portfolio
-
State Street Corp Boston, MA3.99MShares$549 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.3MShares$316 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.25MShares$310 Million0.49% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.1B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...